Biomarker ID | 284 |
PMID | 18550118 |
Year | 2008 |
Biomarker | %[-2]proPSA |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-ID regulation of gene expression,Prostate cancer,Androgen receptor proteolysis and transcription regulation,Androgen receptor signaling, proteolysis, and transcription regulation,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | Prostate Cancer Vs No Cancer |
Type of Biomarker | Diagnostic |
Cohort | 123 men were taken into the study out of which 63 (51%) were cancer cases and 60 (49%) were non cancer controls |
Senstivity | 60% |
Specificity | 70% |
AUC | 0.69 (95% CI: 0.60-0.79) |
Accuracy | NA |
Level Of Significance | p=0.001 |
Method Used | dual monoclonal sandwich assays |
Clinical | No |
Remarks | %[-2] proPSA is defined as [-2] proPSA/fPSA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | KLK3 |